AURORA METALS (BVI) LIMITED (OTCBB: AURMF)
"Up 220.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/AURMF.php

Aurora Metals is a mineral exploration and resource-related company focusing on the exploration and development of its Montana properties. Aurora Metals stock trades under the symbol "AURMF" on the OTC Bulletin Board in the United States of America.

AURMF News:

April 17 - Nevoro to Acquire Aurora Metals (BVI) Limited

Aurora Metals (BVI) Limited (OTCBB: AURMF) (the "Company," "Aurora Metals") announced that it has entered into an arrangement agreement with Nevoro Inc. (Toronto: NVR.TO) pursuant to which Nevoro will acquire 100% of the common shares of Aurora by way of a shareholder and court approved plan of arrangement whereby each Aurora common share will be exchanged for one Nevoro common share. Holders of more than 50% of the outstanding common shares of Aurora have entered into voting agreements with Nevoro pursuant to which they have agreed, among other things, to vote their common shares in favour of the plan of arrangement. The plan of arrangement is expected to complete on or before July 31, 2008.

A copy of the Nevoro news release describing the terms of the transaction and Nevoro's assessment of Aurora's Stillwater's Project, can be viewed at Nevoro Inc. website at www.nevoro.com.

ABOUT NEVORO INCORPORATED

Nevoro is a Canadian exploration company, listed on the Toronto Stock Exchange, currently focused on the discovery of precious metals in Nevada, USA. Nevoro now holds 12 projects in Nevada and one in Idaho, 11 of these projects are wholly owned or optioned and two are currently leased to third parties.

REMOTE DYNAMICS INCORPORATED (OTCBB: RDYM)
"Up 100.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/RDYM.php

Remote Dynamics, Inc. engages in the marketing, sale, and support of automatic vehicle location (AVL) and mobile resource management solutions targeting companies that operate private vehicle fleets in the United States. It designs AVL solutions for metro, short-haul fleets within industry vertical markets, such as field services, distribution, courier, limousine, electrical/plumbing, waste management, and government. The company's product offering includes REDIview, an Internet and service bureau-based software application that provides an array of real-time and accurate mapping, trip replay, and vehicle activity reports. Remote Dynamics also resells T-Mobile GSM data services to its existing vehicle management information customers and provides GSM/GPRS data services to its REDIview customers pursuant to reseller agreements with T-Mobile and Cingular Wireless LLC. The company was incorporated in 1999 and is headquartered in Plano, Texas. Remote Dynamics, Inc. operates as a subsidiary of Bounce Mobile Systems, Inc.

RDYM News:

April 17 - Remote Dynamics Introduces REDI2go, a Portable GPS Solution for Mobile Workers and Subcontractors

Remote Dynamics (OTCBB: RDYM), a leader in GPS asset tracking and fleet management, announces their first truly portable asset tracking solution — REDI2go. REDI2go is a portable device about the size of a cellular phone. Because it requires no installation, it can be easily moved from vehicle to vehicle or carried by a person. REDI2go incorporates all the critical REDIview features such as Geo-Fence alerts, route history and exception reporting like speeding but no longer is required to be permanently installed.

Many companies have come to rely on REDIview software to help them track vehicles, lower fuel usage, cut overtime or verify completed tasks. However, not all companies have been able to realize these benefits because their workers drive their own vehicles or they are temporary subcontractors. This creates headaches for the manager or business partners especially when they are paid by the hour or by the trip. For these situations, installing a fixed device is not an option, but Remote Dynamics now offers a solution with REDI2go's small size and REDIview Software.

Advantages of REDI2go:

– No installation — just charge and go
– No vehicle downtime for set-up
– Hand-out REDI2go units to subcontractors by the job or by the day
– Move from vehicle to vehicle to monitor challenging situations
– Test the benefits of fleet management before installation
– Track the unit all day and get alerts and reports to verify the facts
REDI2go answers the Contractors' most critical questions
– How many hours were spent at the job site?
– How many trips were made from the job site to the materials yard?
– What routes were driven, and were the vehicles in unauthorized areas?
– Where is that worker and when will they arrive at the job site?

"We are pleased to be able to offer new innovative solutions to the contractor or fleet manager," says Gary Hallgren, CEO of Remote Dynamics. "As we continue to listen to our customers, we will continue to enhance our service offering and remain the one-stop-shop for all asset tracking and fleet management needs."

This is one of several new products introduced by Remote Dynamics recently. Early this year they released REDIview 2.1 which included new functions like expanded business rules, private labeling and satellite imagery. For more information, visit www.remotedynamics.com.

ABOUT REDIVIEW

REDIview provides users with business critical information such as vehicle speeding and idling for safety and fuel conservation. It reports current status and asset utilization enabling cost analysis reports for all aspects of the deployment. REDIview offers traditional asset management combined with a robust maintenance module, a strong reporting engine and integration tools. More information on REDIview is available online at www.remotedynamics.com.

ACCENTIA BIOPHARMACEUTICALS INCORPORATED (NASD: ABPI)
"Up 71.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/ABPI.php

Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma; and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development; and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; SinuTest, a test used in connection with the diagnosis of chronic sinusitis; and Zinotic, a treatment of superficial infections of the external ear. This segment's products under development include AllerNase, a formulated suspension of an intranasal topical steroid indicated for the treatment of allergic and non-allergic rhinitis; and Emezine, a product for control of nausea and vomiting. The company was founded in 2002 and is headquartered in Tampa, Florida.

ABPI News:

April 17 - Accentia Announces that After Reviewing Unblinded Results, Independent DMC Recommends Presenting Data on BiovaxID® to FDA and Worldwide Regulatory Agencies in Order to Seek Marketing Approvals for Follicular Non-Hodgkin's Lymphoma

Personalized Medicine Initially Developed at NCI Intended to Stimulate the Patient's Immune System to Seek Out and Destroy Only Cancer Cells in an Indolent But Otherwise Normally Fatal Cancer

Accentia Biopharmaceuticals, Inc. (NASD: ABPI) announced that its majority owned-subsidiary, Biovest International, Inc. (OTCBB: BVTI), reported achievement of a key milestone in Biovest’s mission to gain approval for BiovaxID®, its personalized anti-cancer vaccine, in a pivotal Phase 3 Fast-Tracked clinical trial for the treatment of indolent follicular non-Hodgkin’s lymphoma.

Biovest reported that the independent Data Monitoring Committee (DMC), which is vested with the responsibility of monitoring the safety and efficacy of the BiovaxID trial, has completed a closed session review of the unblinded results, including the primary and secondary endpoints analysis of the Phase 3 study. Based on their analysis, the DMC has recommended that the results be unblinded, and has volunteered to participate, if needed, in Biovest’s ongoing regulatory meetings with the U.S. Food and Drug Administration (FDA) and other worldwide regulatory agencies (Health Authorities) in order to determine the most appropriate process for unblinding the results, and establishing a pathway to seek marketing approvals.

Accentia holds an approximate 76% ownership stake in Biovest, owning more than 73 million shares. Accentia also maintains a 19.5% royalty interest in global sales of BiovaxID.

The Chairman of the DMC, Dr. Gerald Messerschmidt, reported, “Our Committee has completed a closed session unblinded review of the interim Phase 3 safety and efficacy analyses regarding the BiovaxID registration study. Based on this review, the DMC recommends that the BiovaxID study be unblinded to the Company for final analysis. We further suggest that the final clinical study report include data, as part of Biovest's overall regulatory strategy of submission to the regulatory authorities, through August 29, 2008, which is the date when the last randomized and vaccinated patient reaches 12-months follow-up from first injection. While the DMC cannot release information on our closed session discussions, our recommendation to unblind this pivotal registration study in late-August is based on the status of the study, the defined safety profile over 8-years of this Phase 3 registration study and our review of the primary and secondary endpoint analyses. As part of the ongoing regulatory process, I as a representative of the DMC will relate our review of the closed session analysis of these interim data to Health Authorities as necessary.”

Responding to the DMC's recommendations, Biovest's Chairman and CEO, Dr. Steven Arikian, stated, “The DMC's diligent review has resulted in an excellent outcome for BiovaxID. Not only has the Committee reconfirmed the favorable safety profile for BiovaxID, but as importantly, we believe their recommendation to unblind and their willingness to meet with the regulatory authorities to discuss their findings suggests a successful trial outcome. In light of the DMC’s recommendation, we have already been in discussions with regulatory agencies, including the FDA, to seek consensus on the appropriate process for unblinding the results and establishing a pathway for potential accelerated and/or conditional approvals for BiovaxID. We also are coordinating with the EMEA regarding potential market access in Europe. If approved, Biovest will have distinguished itself as the first company to have its anti-cancer vaccine reach market in the U.S. or EU, a Herculean achievement. As this study was initiated in 2000, we now have the largest longitudinal database of lymphoma patients receiving a personalized therapeutic vaccine. 234 patients were enrolled and 177 randomized in the Phase 3 trial of which, two-thirds received BiovaxID therapy, and one-third control treatment. We believe that these long-term and highly anticipated results will demonstrate that BiovaxID is capable of prolonging the period of disease-free survival for an incurable form of non-Hodgkin's lymphoma, and in some cases, perhaps even inducing indefinitely prolonged, durable remissions.”

As previously presented to the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), the National Cancer Institute (NCI) demonstrated in a Phase 2 clinical trial that patients treated with BiovaxID achieved: a median disease-free survival of over eight years; a 95% overall survival rate after 9.2 years of follow-up; and a 95% cellular immune response. In this clinical trial, 73% of evaluable patients were converted into molecular remission (bcl-2 negative), evidence that their blood has been cleared of residual cancerous cells. BiovaxID also demonstrated an outstanding safety profile.

According to Dr. Angelos M. Stergiou, Biovest's Vice President, Product Development, Medical Affairs & Clinical Research, “This Phase 2 data, combined with our analysis of the blinded Phase 3 results, and the DMC’s recommendation to unblind, gives us a high level of confidence in unblinding the current Phase 3 study, both for efficacy and safety. If the results are highly positive, and assuming we are granted accelerated approval for BiovaxID, we would anticipate initiating a Phase 4, post-approval, clinical study for the purpose of collecting further efficacy and safety data.”

The primary end-point of the trial is a comparison between treatment groups, those that receive BiovaxID and those that receive a control. The study is looking at duration of disease-free survival measured from the time of randomization (i.e. when a subject is randomly assigned to receive BiovaxID or control) to the time of confirmed relapse.

“The National Cancer Institute’s (NCI) development of this potentially revolutionary technology is truly an extraordinary story,” stated Dr. Frank E. O’Donnell Jr., Vice-Chairman of Biovest and Chairman and CEO of Accentia Biopharmaceuticals. “Based on pioneering work done at Stanford University by Dr. Ronald Levy and colleagues, the NCI exclusively funded the development of BiovaxID from preclinical animal models right through an IND to initiation of a pivotal Phase 3 study. These investigators wanted to determine if an anti-cancer vaccine, BiovaxID, is capable of recruiting the immune system of cancer patients to recognize and effectively destroy cancer cells, after chemotherapy had debulked the tumor in order to break immune tolerance. By efficiently creating a high fidelity copy of the patient’s tumor-specific antigen using a fully automated Biovest-designed bioreactor, conjugating the antigen to a foreign carrier protein, and boosting the immune system, NCI reasoned that it could provide patients with an active immune response to their cancers and provide protection by means of an ongoing immunosurveillance against recurrence of the cancer. In Phase 2 studies at NCI and independent clinical studies elsewhere, it appears that 80% of immunized patients mount a detectable immune response with meaningful clinical effects.”

In other news, Accentia announced the appointment of Christopher Chapman, M.D. to its Board of Directors, bringing a wealth of experience as an accomplished physician and as an expert in multiple biopharmaceutical senior executive roles including overseeing drug safety matters, managing pharmacovigilance, and steering clinical operations and regulatory affairs. He served in these roles with leading companies including Organon Pharmaceuticals (now a Schering Plough Company) and Quintiles, a clinical research organization. Dr. Chapman received his M.D. degree from Georgetown University in Washington D.C., where he completed his internship in Internal Medicine.

Dr. Chapman replaces Mr. John P. Dubinsky on the Board, as Mr. Dubinsky has resigned to focus on other business-related and charitable interests, including his active role in various non-profit organizations. Mr. Dubinsky’s resignation was amicable, and not a result of any disagreement with the Company or related to its operations, policies or practices.

ABOUT BIOVAXID®

BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.

About Accelerated Approval under Subpart E (21CFR 601, Subpart E, Accelerated Approval of Biological Products for Serious or Life-Threatening Illnesses)

FDA may accelerate approval of certain new biological products for serious or life-threatening illnesses, with provisions for any necessary continued study of the drugs' clinical benefits after approval or with restrictions on use, if necessary. Subpart E is intended to provide expedited marketing of biological products for patients suffering from such illnesses when the biological products provide meaningful therapeutic benefit compared to existing treatments. Accelerated approval will be considered in two situations: (1) When approval can be reliably based on evidence from adequate and well-controlled studies of the drug's effect on a surrogate endpoint that reasonably suggests clinical benefit or on evidence of the drug's effect on a clinical endpoint other than survival or irreversible morbidity, pending completion of studies to establish and define the degree of clinical benefits to patients; and (2) when FDA determines that a drug, effective for the treatment of a disease, can be used safely only if distribution or use is modified or restricted. Drugs or biological products approved under these procedures must have met the requisite standards for safety and effectiveness under the Federal Food, Drug, and Cosmetic Act (the act) or the Public Health Service Act (the PHS Act) and, thus, will have full approval for marketing.

EXPERT GROUP INCORPORATED (OTC: EXPT)
"Up 53.85% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/EXPT.php

Expert Group, Inc. is a diversified financial services company which markets a variety of financial products and services through Expert Financing, Expert Group Title Services, Expert Credit Fix USA. Expert is licensed by the department of Financial Regulations and a member of FAMB, and since inception, Expert has originated over $50 million in origination. The Company offers a stock option plan to its loan officers, brokers, title agents, and processors.

EXPT News:

April 17 - Expert Group, Inc. Announces Stock Buy Back Plan

Expert Group, Inc. (OTC: EXPT), specializing in refinance loans, home mortgage loans, and new home purchases as well as foreign national loans, and now offering a range of credit repair services through its sister company, Expert Credit Fix USA, announced that effective immediately its officers and directors will be buying shares in the open market. As part of this process, this week we will be buying back 5 million shares. We appreciate all the support we have being receiving from our current shareholders.

Robert Rico, C.E.O. of Expert Group, states, "As part of our on going commitment to brand Expert, we feel we also need to support our share price so I will be personally purchasing shares in the open market starting immediately. I thank all past, present and future shareholders for being part of Expert."

SIGNATURE DEVICES (OTC: SDVI)
"Up 52.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/SDVI.php

Signature Devices, Inc. engages in the development, manufacture, and sale of information technology products in the United States. The company creates, develops, and publishes 3-D interactive games for consoles and personal computers. It also publishes software for video games and commercial products. The company publishes games for consoles, such as GBA, XBox360, and Playstation. In addition, the company provides consulting for information technology, including computer systems, software, and electronic products. It offers a platform for hardware, embedded systems development, and image generation technology, which can be used in films, videogames, and the military. Further, the company develops customized 3D identities, including lighting, shading, artificial intelligence, and animation systems. Signature Devices was founded in 2002 and is headquartered in Redwood City, California.

SDVI News:

April 17 - Signature Devices, Inc.'s Wholly Owned Subsidiary's Video Games Made Available on Amazon.com, One of the World's Largest E-Commerce Web Sites

Signature Devices, Inc. (OTC: SDVI) announced that several of the company's video game titles are now available on Amazon.com, through its subsidiary Graffiti Entertainment, LLC. Amazon.com has 14 different products from Graffiti Entertainment, including the Gameboy Advance version of Mazes of Fate. Five of the 14 featured products are available as pre-orders in anticipation of their individual releases throughout the year.

Amazon.com, a Fortune 500 company, was one of the first companies to sell goods over the Internet and is currently one of the largest and most diversified e-commerce Web sites in the world. The site attracts over 615 million unique visits each year, more than twice the number of Walmart.com, whose Web site is powered by Amazon.com, who also powers Target.com, Borders, Waldenbooks, Sears Canada and other various e-Commerce Web sites.

"We are excited to have expanded our product reach to be included on one of the world's largest and popular e-commerce sites. We believe that Amazon.com will create a great deal of momentum for upcoming product releases that are already available for pre-orders," stated Kenneth Hurley, CEO of Signature Devices, Inc. and Graffiti Entertainment, LLC.

To view the available video games, visit:

www.amazon.com/exec/obidos/search-handle-url?%5Fencoding=UTF8&store-name=videogames&search-type=ss&index=videogames& field-brandtextbin=Graffiti%20Entertainment

ABOUT SIGNATURE DEVICES, INC. AND GRAFFITI ENTERTAINMENT, LLC:

Based in Redwood City, Calif., Signature Devices, Inc. creates, develops and manufactures advanced information technology, including computer systems, software and electronics products. One of the Company's premier technologies includes a blend of hardware and software for image generation technology used in video games and simulations. Signature Devices also owns Graffiti Entertainment, LLC, (www.GraffitiEntertainment.com), a publisher of interactive entertainment software for advanced entertainment consoles.

WELWIND ENERGY INTERNATIONAL (OTCBB: WWEI)
"Up 51.11% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/WWEI.php

Welwind Energy International Corp. is committed to providing the best resource option available for renewable energy, protecting our environment, empowering communities, bolstering local economies and respecting the rights of future generations. Welwind Energy International was founded to build, own and operate wind farms on an international scale. The company's goal is to become a leading provider of clean energy products for the residential, business and governmental consumer.

WWEI News:

April 16 - Welwind Energy International Investor Conference Call Available On Corporate Website

Welwind Energy International Corp.'s (OTCBB: WWEI) (the “Company”) year-end investor conference call, which took place on Monday, April 14, 2008 at 11:00 a.m. PDT, is available for downloading off of the company Web site. Please follow the link below to access and then click on the April 14th news release:

www.welwind.com/ir-news_releases.php

Tammy McNabb, President and Director; Shannon de Delley, Managing Director; and Luis Carillo, Internal Counsel, gave a detailed update on the progress that the Company has made in the past quarter as well as what is anticipated in the near future.